Alumis Presents 28-Week Data From Open Label Extension Period Of Phase 2 STRIDE Trial Of ESK-001; Says '28-week Data Show ESK-001 Was Generally Well Tolerated and Most Patients Treated With the Top Dose of 40 Mg Twice Daily Achieved PASI 75'
Alumis Presents 28-Week Data From Open Label Extension Period Of Phase 2 STRIDE Trial Of ESK-001; Says '28-week Data Show ESK-001 Was Generally Well Tolerated and Most Patients Treated With the Top Dose of 40 Mg Twice Daily Achieved PASI 75'
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.